Given that Fulvestrant can reduce FOXM1 expression (Figure 8A) and that the combination of Fulvestrant and TLR4-specific inhibitor CLI−095 prevents the metastasis of NSCLC effectively [66], it is of potential significance to investigate the role of FOXM1 in Fulvestrant against NSCLC. The gene discussed is FOXM1; the disease is non-small cell lung carcinoma.